A Phase II Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist
Latest Information Update: 15 May 2025
At a glance
- Drugs AZD-6234 (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms ARAY
- Sponsors AstraZeneca
Most Recent Events
- 11 Apr 2025 Planned End Date changed from 9 Jan 2026 to 27 Jan 2026.
- 11 Apr 2025 Planned primary completion date changed from 9 Jan 2026 to 27 Jan 2026.
- 11 Apr 2025 Status changed from not yet recruiting to recruiting.